Series B · Medtech & Devices · Milan, Italy · Founded 2016 · 25–50 employees
Newronika develops adaptive deep brain stimulation (DBS) systems that respond to the brain's own signals in real-time for treating Parkinson's disease. The company's CE-marked αDBS therapy uses patented proportional control algorithms and cloud-based intelligence to automatically adjust stimulation parameters, offering more precise treatment with fewer side effects compared to conventional fixed-dose DBS. Founded as a spin-off from the University of Milan and Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital, the company recently raised €13.6 million in Series B funding and received FDA IDE approval to begin US clinical trials. Their platform represents a breakthrough in closed-loop neuromodulation technology with potential applications beyond Parkinson's to epilepsy and depression.
No open roles listed right now.